← All trials
NCT07142408
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2023
- Primary completion
- Oct 31, 2030
- Completion date
- Dec 31, 2030
- First posted
- Aug 26, 2025
- Last posted
- Aug 26, 2025
- Enrollment
- 848
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The Cleveland ClinicCollaborator
- University of California, DavisCollaborator
- University of GeorgiaCollaborator
- Washington University in St. LouisCollaborator
- Baylor UniversityCollaborator
- Temple UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.